Patient-reported outcomes with anastrozole versus tamoxifen for postmenopausal patients with ductal carcinoma in situ treated with lumpectomy plus radiotherapy (NSABP B-35): a randomised, double-blind, phase 3 clinical trial

详细信息    查看全文

• 作者：Prof Patricia A Ganz ; MD^a ; ^b ; ^{pganz@mednet.ucla.edu" class="auth_mail" title="E-mail the corresponding author} ; Reena S Cecchini ; PhD^c ; ^d ; Prof Thomas B Julian ; MD^a ; ^e ; Prof Richard G Margolese ; MD^a ; ^f ; Joseph P Costantino ; DrPH^c ; ^d ; Laura A Vallow ; MD^a ; ^g ; Prof Kathy S Albain ; MD^a ; ^h ; ⁱ ; Patrick W Whitworth ; MD^a ; ^j ; ^k ; Mary E Cianfrocca ; DO^a ; ^h ; ^l ; ^m ; Prof Adam M Brufsky ; MD^a ; ⁿ ; Howard M Gross ; MD^a ; ^o ; Prof Gamini S Soori ; MD^a ; ^p ; Judith O Hopkins ; MD^a ; ^q ; ^r ; Louis Fehrenbacher ; MD^a ; ^s ; Keren Sturtz ; MD^a ; ^t ; Timothy F Wozniak ; MD^a ; ^u ; Thomas E Seay ; MD^a ; ^v ; Eleftherios P Mamounas ; MD^a ; ^w ; Prof Norman Wolmark ; MD^a ; ^e
• 刊名：The Lancet
• 出版年：2016
• 出版时间：27 February-4 March 2016
• 年：2016
• 卷：387
• 期：10021
• 页码：857-865
• 全文大小：509 K

文摘

The NSABP B-35 trial compared 5 years of treatment with anastrozole versus tamoxifen for reducing subsequent occurrence of breast cancer in postmenopausal patients with ductal carcinoma in situ. This report assesses the effect of these drugs on quality of life and symptoms.

Methods

The study was done at 333 hospitals in North America. Postmenopausal women with hormone-positive ductal carcinoma in situ treated by lumpectomy with clear resection margins and whole breast irradiation were randomly assigned to receive either tamoxifen (20 mg/day) or anastrazole (1 mg/day) for 5 years, stratified by age (<60 years m>vsm> ≥60 years). Patients and investigators were masked to treatment allocation. Patients completed questionnaires at baseline and every 6 months thereafter for 6 years. The primary outcomes were SF-12 physical and mental health component scale scores, and vasomotor symptoms (as per the BCPT symptom scale). Secondary outcomes were vaginal symptoms and sexual functioning. Exploratory outcomes were musculoskeletal pain, bladder symptoms, gynaecological symptoms, cognitive symptoms, weight problems, vitality, and depression. We did the analyses by intention to treat, including patients who completed questionnaires at baseline and at least once during follow-up. This study is registered with ClinicalTrials.gov, NCT00053898.

Findings

Between Jan 6, 2003, and June 15, 2006, 3104 patients were enrolled in the study, of whom 1193 were included in the quality-of-life substudy: 601 assigned to tamoxifen and 592 assigned to anastrozole. We detected no significant difference between treatment groups for: physical health scores (mean severity score 46&middot;72 for tamoxifen m>vsm> 45&middot;85 for anastrozole; p=0&middot;20), mental health scores (52&middot;38 m>vsm> 51&middot;48; p=0&middot;38), energy and fatigue (58&middot;34 m>vsm> 57&middot;54; p=0&middot;86), or symptoms of depression (6&middot;19 m>vsm> 6&middot;39; p=0&middot;46) over 5 years. Vasomotor symptoms (1&middot;33 m>vsm> 1&middot;17; p=0&middot;011), difficulty with bladder control (0&middot;96 m>vsm> 0&middot;80; p=0&middot;0002), and gynaecological symptoms (0&middot;29 m>vsm> 0&middot;18; p<0&middot;0001) were significantly more severe in the tamoxifen group than in the anastrozole group. Musculoskeletal pain (1&middot;50 m>vsm> 1&middot;72; p=0&middot;0006) and vaginal symptoms (0&middot;76 m>vsm> 0&middot;86; p=0&middot;035) were significantly worse in the anastrozole group than in the tamoxifen group. Sexual functioning did not differ significantly between the two treatments (43&middot;65 m>vsm> 45&middot;29; p=0&middot;56). Younger age was significantly associated with more severe vasomotor symptoms (mean severity score 1&middot;45 for age <60 years m>vsm> 0&middot;65 for age ≥60 years; p=0&middot;0006), vaginal symptoms (0&middot;98 m>vsm> 0&middot;65; p<0&middot;0001), weight problems (1&middot;32 m>vsm> 1&middot;02; p<0&middot;0001), and gynaecological symptoms (0&middot;26 m>vsm> 0&middot;22; p=0&middot;014).

Interpretation

Given the similar efficacy of tamoxifen and anastrozole for women older than age 60 years, decisions about treatment should be informed by the risk for serious adverse health effects and the symptoms associated with each drug. For women younger than 60 years old, treatment decisions might be driven by efficacy (favouring anastrozole); however, if the side-effects of anastrozole are intolerable, then switching to tamoxifen is a good alternative.

Funding

US National Cancer Institute, AstraZeneca Pharmaceuticals.